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Abstract
The demonstration of impaired complement regulation in the thrombotic
microangiopathy, atypical haemolytic uraemic syndrome (aHUS) has resulted in the
successful introduction of the complement inhibitor eculizumab into clinical practice.
Complement abnormalities account for approximately 50% of aHUS cases however
recently mutations in the non-complement gene DGKE have been described in
individuals not responsive to eculizumab.
We report here a family where the proposita presented with aHUS but did not
respond to Eculizumab. Her mother had previously presented with a post renal
transplant thrombotic microangiopathy (TMA). Both also had Charcot Marie Tooth
(CMT). Using whole exome sequencing we identified a mutation in INF2 in the
mutational hotspot for focal segmental glomerulosclerosis (FSGS). Subsequent
analysis of the Newcastle aHUS cohort identified another family with a functionally
significant mutation in INF2. In this family renal transplantation was associated with
post transplant TMA. In all individuals with INF2 mutations presenting with a TMA,
aHUS risk haplotypes were also present, potentially accounting for the genetic
pleiotropy.
Identifying individuals with TMAs who may not respond to eculizumab will avoid
prolonged exposure of such individuals to the infectious complications of terminal
pathway complement blockade.
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Genetic abnormalities in the alternative pathway of complement have been
demonstrated to account for many cases of the thrombotic microangiopathy (TMA)
atypical haemolytic uraemic syndrome (aHUS)(MIM 235400)1. Understanding the role
of complement in the pathogenesis of aHUS has resulted in the successful introduction
of the complement inhibitor eculizumab into clinical practice2.
Recently mutations in the non-complement gene DGKE have been demonstrated
to be associated with aHUS (MIM615008)3. Individuals with DGKE mutations display
phenotypic variability with some patients presenting with membranoproliferative
glomerulonephritis4. As might be expected with a genetic cause which does not appear
to be complement mediated, individuals have not responded to treatment with
eculizumab3.
Despite recent advances, the genetic basis of many cases of familial aHUS remain
unsolved. In this study we describe the finding of INF2 mutations in two families with
TMA.
Our index case, patient III:2 presented aged 7 with pex cavus and difficulty walking
and was diagnosed with Charcot-Marie-Tooth (CMT) (figure 1). Aged 15 she
presented 5 days after a sore throat with microangiopathic haemolytic anaemia on
blood film (Hb, 9.4 g/dl), thrombocytopenia (platelets 119 ×109/L) and renal failure
(creatinine 879 µmol/l). Haptoglobins were undetectable, LDH was 844 U/L and there
was proteinuria (4.8g/l). Blood pressure on admission was 185/110 mm Hg.
Haemodialysis was commenced at presentation and plasma exchange was
undertaken prior to commencement of eculizumab. Initially there was an improvement
in the platelet count to 173 ×109/L but subsequently this fell to 100 ×109/L. A bone
marrow biopsy was unremarkable and trough eculizumab concentration was adequate
with a completely suppressed CH50. Three months after presentation a renal biopsy
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was undertaken demonstrating characteristic changes of a thrombotic
microangiopathy (figure 2a). There were also features of a distinct glomerulosclerosis
with small glomeruli and arteriosclerosis (figure 2b). After 9 months with no renal
recovery eculizumab was withdrawn.
Screening for known inherited and acquired causes of aHUS did not reveal any
abnormality1. The C5 variant c.2654G>A, (p.R885H) which impairs eculizumab
efficacy was not present5.
Family history revealed that the proposita’s mother, patient II:2 (figure 1), also had
CMT, had presented with ESRF aged 17 and had a post transplant TMA (figures 2d,e)
(case history supplementary data).
Due to the absence of an abnormality in a known aHUS associated gene we
sequenced the exomes of the two affected individuals in this family.
This revealed a rare variant in INF2, c.305T>A (p.V102D) (figure 1). Mutations in
INF2 are the commonest cause of familial autosomal dominant nephrotic syndrome6-
8. In a minority of these cases the mutations cause a syndromic form of Focal
Segmental Glomerulosclerosis (FSGS) associated with the demyelinating peripheral
neuropathy, CMT 9, 10 (figure 3).
To assess whether mutations in INF2 account for other cases of familial or sporadic
TMA previously referred to the Newcastle aHUS centre11 we analysed 28 familial
cases by exome sequencing and undertook Sanger sequencing on an additional 161
sporadic aHUS cases. In one family, in which no known genetic risk factors had been
found, we identified a functionally significant mutation in INF2, c.530G>A (p.R177H),
which segregated with the disease (supplementary data, Figures 1,2). No INF2
variants were identified in sporadic aHUS cases.
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INF2 is a ubiquitously expressed formin protein12 which accelerates actin
polymerization and depolymerisation, thus regulating a range of cytoskeleton
dependent cellular functions including the secretory pathway 13, 14. INF2 comprises
formin homology 1 and 2 domains (FH1 and FH2); an N-terminal diaphanous inhibitory
domain (DID) and a C-terminal diaphanous autoregulatory domain(DAD)15. Mutations
in INF2 predominate in the DID domain6, 7, 10. Functional analysis of INF2 mutations in
disease has demonstrated disorganised cytoskeletal functions7, 9 although the precise
mechanism of disease remains elusive.
The two INF2 variants we describe here reside in the mutational hotspot for disease
6-10. The c.305T>A (p.V102D) variant resides in exon 2 while c.530G>A (p.R177H)
resides in exon 4 (figure 3, 4). Structural modelling reveals that the p.V102D variant
is in close proximity to the DAD binding region. Modelling does not predict a surface
exposed residue but instead the variant may be expected to disrupt the architecture
of the 8th α-helix of the DID domain (Figure 4). The p.R177H variant resides before 
the 13th α-helix of the DID domain and is surface exposed (figure 4). Amino acids at 
both these positions are conserved across species with GERP++ scores of 4.76
(p.V102D) and 4.48 (p.R177H) (figure 1).
Disease-causing mutations in FSGS, have mainly been found to occur in the DID
domain, in exons 2-4, with only one report of a mutation in exon 6 (figure 3)6-8, 16. Within
this hot-spot there is a cluster between nucleotides 300 and 500 which accounts for
those with FSGS and CMT9, 10. The p.V102D mutation resides in this region and this
family have CMT while the p.R177H mutation resides downstream of this region and
this family has no neurological phenotype. The p.R177H mutation has previously been
reported in 3 unrelated pedigrees and in all cases had the non-syndromic form of
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FSGS6, 8. Functional analysis of this mutation demonstrated altered INF2 localisation
and disruption of the actin cytoskeleton9.
It is well reported that even in individual families with the same INF2 mutation there
is phenotypic variability. Most commonly individuals present with disease in
adolescence with mild proteinuria, developing ESRF in the 3rd or 4th decade, although
individuals have been reported to be unaffected into their 6th or 7th decade16. Variable
intrafamilial penetrance has also been reported for the neurological phenotype16. The
clinical and pathological disease pleiotropism we describe with INF2 mutations is also
seen in individuals with recessive DGKE mutations where some individuals present
with proteinuria and progressive renal failure while others present with aHUS. Likewise
the biopsy findings in DGKE associated disease are also heterogenous ranging from
a membranoproliferative pattern to a TMA. These findings can vary according to the
time of presentation. It is only with genetic analysis that the underlying pathological
process can be identified and a therapeutic intervention sought. It has been suggested
that genetic background or environmental factors modify the penetrance and
phenotype of disease16, 17. It is interesting to note that in family 1 both affected
members, II:2 and III:2, were both homozygous for the aHUS at-risk CFH-H3
haplotype18, and both carried one risk CD46 allele19. In family 2, patient III:1 was
homozygous for the CD46GGAAC risk haplotype while III:2 was heterozygous. III:1 also
carried one copy of the CFH-H3 haplotype (figure 1).
Although INF2 mutations have not previously been associated with a renal
thrombotic microangiopathy, aHUS has been reported in patients with primary
FSGS20-23 and FSGS is a frequent pathological sequalae of sporadic Stx-HUS24. A
thrombotic microangiopathy has also been associated with other causes of nephrotic
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syndrome25, 26 and primary glomerulonephritis including IgA nephropathy27-29; Henoch
Schonlein Purpura23; ANCA associated vasculitis22, 23; and anti-GBM nephropathy23.
It has been hypothesised that either direct or indirect (via impaired VEGF secretion
from podocytes) endothelial injury leads to a constricted microvasculature with
perturbed haemodynamic flow leading to the formation of platelet microthrombi and a
thrombotic microangiopathy. Loss of coagulation regulators with upregulation of
procoagulation factors has also been suggested as a contributory factor in those
individuals with co-existent nephrotic syndrome 30-33.
It is intriguing that all 3 patients who had renal transplants had biopsy proven
evidence of a thrombotic microangiopathy in their renal allografts. The risk of FSGS
recurrence post transplant in those with genetic defects of the glomerular filtration
barrier is low due to correction of the underlying defect34-36. An exception to this is in
those individuals with complete deficiency of NPHS1 due to the presumed generation
of antibodies against this immunologically novel protein in the allograft. Such a
scenario would not be expected in a dominantly inherited condition.
Currently, there is little information available as to the recurrence of FSGS post
transplantation in individuals carrying INF2 mutations. However, in one small study
recurrence was seen in one of three individuals8. INF2 is expressed ubiquitously12 and
recurrence of FSGS in an allograft suggests that a circulating factor or cell type is
predisposing to recurrent disease. Such a factor may account for post transplant TMA.
It should be noted that INF2 has been demonstrated to complex with and alter the
intracellular transport of the complement regulators CD55 and CD59 which are present
on all circulating cells including platelets. We cannot however rule out the possibility
that the TMA was a consequence of the post-transplant milieu (eg, viral diseases,
ischemia reperfusion injury, donor-specific antibodies, immunosuppressive drugs).
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In summary we describe two families with mutations in INF2 in addition to common
aHUS risk haplotypes who present with aHUS or a post transplant TMA. Eculizumab
was unsuccessful in preventing either ongoing TMA or ESRF as is seen with other
non-complement mediated causes of aHUS. Indentifying individuals who will not
respond to eculizumab will avoid exposing these individuals to the infectious risks of
terminal pathway complement blockade. This study represents an initial application of
whole-exome sequencing in personalised management of TMA.
Concise Methods
The study was approved by Newcastle and North Tyneside 1 Research Ethics
Committee, and informed consent was obtained in accordance with the Declaration of
Helsinki.
Complement Assays
C3 and C4 levels were measured by rate nephelometry (Beckman Coulter Array
360). FH levels were measured by radial immunodiffusion (Binding Site). Screening
for complement autoantibodies were undertaken using ELISA as described
previously37, 38.
Genetic Analysis and Multiplex ligation-dependent probe amplification
Mutation screening of CFH39, CFI40, CFB41, MCP42, C343, and DGKE3 was
undertaken using Sanger sequencing as previously described. Screening for genomic
disorders affecting CFH, CFHR1, CFHR2, CFHR3, CFHR5, CFI and CD46 was
undertaken using multiplex ligation-dependent probe amplification (MLPA)44, 45.
Mutation screening of INF2 was undertaken using Sanger sequencing using the primer
conditions in supplemental table 5.
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Whole exome sequencing
Enrichment from isolated DNA was performed using either Illumina Nextera Rapid
Capture Exome by AROS AB (family 1) or Agilent SureSelectXT Human All Exon V5
by GATC Biotech, Konstanz (family 2, III:1) as described previously46. Library
preparation was performed post-capture, with adaptor sequences and indexing
incorporated using proprietary methods of AROS AB and GATC Biotech, compatible
for Illumina sequencing technology. Illumina sequencing was performed on the
HiSeq2000 instrument (v3 chemistry)(Supplemental table 2).
The quality of sequencing reads was firstly checked with FastQC 47. Duplicated
reads were removed with FastUniq 48. The remaining reads were mapped to the
human reference genome GRCh37 with BWA 49. The alignments were refined with
tools of the GATK suite 50. Variants were called according to GATK Best Practice
recommendations 51, 52, including recalibration. Freebayes was also used to call
variants from the same set of samples 53. The variants called by Freebayes with total
coverage ≥ 5, minor allele coverage ≥ 5 and variants call quality ≥ 20 were added to 
those identified by GATK. Annovar was used for annotations and prediction of
functional consequences 54. Variants identified in family 1 were filtered as detailed
(Supplemental table 2). First, we selected for variants in high impact regions and
selected variants at a minor allele frequency (MAF) <5% in 1000G and ESP6500. We
then selected those variants segregating in a dominant fashion with disease. Variants
predicted to be deleterious by Polyphen-2 HDIV and HVAR, Mutation Taster, Mutation
Assessor, FATHMM or RadialSVM were selected for further analysis. A more stringent
MAF cut-off of <0.1% in 1000G and ESP6500 was applied and non-conserved variants
(<2 by GERP++ and <0.5 by PhyloP) were discarded (Supplemental table 3).
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Phenotypic data was then used to interrogate the remaining 34 genes providing only
one candidate gene known to have both renal and neurological conditions inherited in
an autosomal dominant pattern (Supplemental table 4).
Protein modelling
Phyre2 was used to generate an approximate protein structure using the inputted
amino acid sequence of INF2 (NP 071934.3, amino acids 1-250) using the intensive
modelling mode. Protein domain boundaries for INF2 were taken from Pfam55.Three-
dimensional protein structures were manipulated using PyMOL 56
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Figure Legends
Figure 1 Pedigrees of families with Inverted formin 2 (INF2) genetic variants. The
pedigrees demonstrate the segregation of the renal / neurological phenotype with the
rare genetic variant, c.305T>A (p.V102D) in family 1 (a) and c.530G>A (p.R177H) in
family 2 (d). Individuals tested but not carrying the mutation are shown – nmd (no
mutation detected). The number of alleles carrying the aHUS risk haplotype CFH-H3
(CFHrisk) and CD46GGAAC (CD46risk) are shown on the pedigree. Sanger sequencing
trace of wild type (WT) and mutant (Mut) for c.305T>A (p.V102D) (b) and c.530G>A
(p.R177H) (e). Alignment of human, chimpanzee, orangutan, mouse, rat, dog,
opossum, platypus and zebrafish INF2 demonstrating amino acid conservation (c, f)
(performed using http://genome.ucsc.edu/cgibin/hgTrackUi?hgsid=309786867&c=
chr21&g=cons46way#a_cfg_phyloP).
Figure 2 Renal biopsies. Native renal biopsy from family 1, patient III:2. (a) Two
arterioles (right) showing features of active thrombosis and a small artery (left) with
relatively slight intimal oedema with fibrosis, Hematoxylin and eosin stain (H&E). (b)
Glomerulus (left) showing global sclerosis and occluded arteriole (right), Periodic acid–
Schiff (PAS). Native renal biopsy from family 1, patient II:2 demonstrating end-stage
changes with diffuse global sclerosis (c). Renal transplant biopsy from family 1 patient
II:2 demonstrating (d) an occluded arteriole (PAS) and (e) a capillary loop with
abundant subendothelial fluffy material (Electron microscopy). Native renal biopsy
from family 2, patient III:2 demonstrating (f) a sclerosed glomeruli and (g) a segmental
sclerosing lesion. Renal transplant biopsy from family 2 patient III:1. Mucoid intimal
thickening is seen in an interlobular artery with red cell fragmentation in the wall and
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luminal thrombus (h). Mesangiolysis is also seen 3-6 o’clock (i) (silver stain). Native
renal biopsy from family 2, patient III:2 showing a subacute/chronic arterial TMA with
fibroproliferative obliteration of small arteries and arterioles (J) (H&E) and (K)
(trichrome). Renal transplant biopsy from family 2, patient III:2 demonstrating end
stage change with fibrous obliteration of arteries. (l)(H&E)
Figure 3 Inverted formin 2 (INF2) variants in FSGS, CMT and aHUS. A
representation of the domain structure of INF2 showing the diaphanous inhibitory
domain (DID), formin homology domains (FH1, FH2) and the diaphanous
autoregulatory domain (DAD). Genetic variants associated with isolated FSGS are
below the domain structure. Genetic variants with a combined FSGS/CMT phenotype
are shown above the domain structure. Variants from Mademan et al57. The locations
of the aHUS associated mutations demonstrated in the study are shown in red.
Figure 4 Predicted structure of diaphanous inhibitory domain (DID) of Inverse
Formin 2 (INF2). A structural model of the DID domain (amino acids 1-234) was
generated using Phyre2 (a)58. Blue spheres represent the amino acids involved in
binding to DAD domain: (R106, N110, A149, I152). The position of the p.V102D and
R177H mutations are highlighted in red. The p.V102D lies in the 8th α-helix  of the DID 
(amino acids) domain. (b) Surface representation of the modelled structure
highlighting the surface exposed amino acids responsible for DAD binding (R106,
N110, A149, I152). The mutant p.V102D is not buried but may be expected to disrupt
the architecture of the 8th α-helix. The p.R177H variant resides before the 13th α-helix 
of the DID domain and is surface exposed .
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